Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-04-08 00:00:00 ET · period of report 2022-04-07 · accession 0000899243-22-014360 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-04-08 | 2022-04-07 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $276.18 | -561 | 42.8K | -1% | -$154.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-07 | S | D | 204 | $275.71 | 43,139 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $275.71 (range $275.00 to $275.95). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-04-07 | S | D | 327 | $276.39 | 42,812 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $276.39 (range $276.00 to $276.78). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2022-04-07 | S | D | 30 | $277.02 | 42,782 | D | — | — |